NCT02341508View on ClinicalTrials.gov

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy Subjects
Interventions
BIOLOGICAL

0.5 mg/kg Lpathomab

BIOLOGICAL

1.0 mg/kg Lpathomab

BIOLOGICAL

3.0 mg/kg Lpathomab

BIOLOGICAL

10 mg/kg Lpathomab

BIOLOGICAL

20 mg/kg Lpathomab

OTHER

Saline solution for intravenous infusion

Trial Locations (1)

84106

PRA Health Sciences, Salt Lake City

All Listed Sponsors
lead

Lpath, Inc.

INDUSTRY

NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers | Biotech Hunter | Biotech Hunter